Fulgent Genetics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY Revenue (est.)
$350.9Mnext fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly71.1MTarget: 350000000 (Full Year 2026 Guidance)
Non-GAAP Net Loss per Share Quarterly-0.4Target: -1.59 (Full Year 2026 Guidance)
Cash, Cash Equivalents, and Marketable Securities Quarterly604.7MTarget: 636000000 (Expected Year-End 2026)
Watch Items
- Customer Concentration RiskTrigger: Largest customer revenue share falling below 15%Action: Monitor diversification progress and onboarding of new enterprise accounts to offset the loss of legacy high-volume accounts.
- Therapeutic Development Cash BurnTrigger: Annual therapeutic spend exceeding $26 millionAction: Evaluate clinical trial progression timelines for FID-007 and FID-022 to ensure disciplined capital allocation.
- IRS Tax Refund DelayTrigger: Failure to receive $106 million in tax refunds by Q4 2026Action: Adjust year-end cash projections and evaluate potential impacts on the stock repurchase program.
Research as of 19 Jun 2026